• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Berwick Donald M

    5/10/24 4:08:10 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Berwick Donald M

    (Last) (First) (Middle)
    C/O NATIONAL RESEARCH CORPORATION
    1245 Q STREET

    (Street)
    LINCOLN NE 68508

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NATIONAL RESEARCH CORP [ NRC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Director Stock Option (Right to Buy) $29.76 05/08/2024 A 10,906 (1) 05/08/2034 Common Stock 10,906 $0 10,906 D
    Explanation of Responses:
    1. This award is an annual grant to the reporting person made under the Issuer's 2004 Non-Employee Director Stock Plan (the "Plan") on the date of the Issuer's 2024 annual shareholder meeting. In accordance with the terms of the Plan, the award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to certain exceptions provided in the Plan.
    /s/ Donald M. Berwick, by Heidi Hornung-Scherr, attorney-in-fact, pursuant to a POA previously filed with the SEC 05/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Freeman Jordan Nicole bought $10,000 worth of shares (771 units at $12.97) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    8/4/25 4:40:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    5/13/25 11:30:22 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRC Health Named #1 Best in KLAS Again for Healthcare Experience Management

    NRC Health, a leader in healthcare-built technology and data-driven insights advancing Human Understanding in care delivery, today announced it has received the 2026 Best in KLAS Award for Healthcare Experience Management for the third time in four years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204821939/en/ This honor highlights NRC Health's long-standing leadership in healthcare experience management, built on more than 40 years of innovation and collaboration. "This recognition reflects the dedication of our team and the trust our partners place in us," said Trent Green, CEO of NRC Health. "For more than four deca

    2/4/26 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Fourth Quarter 2025 Results

    Fourth quarter TRCV* increased 8% year-over-year to $144.1 million Cash flow from operations increased 13% year-over-year to $7.2 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the fourth quarter 2025. "Our fourth quarter results reflect the strong, disciplined execution happening across NRC Health and the deep trust our customers place in us," said Trent Green, CEO of NRC Health. "With TRCV reaching $144 million and momentum building across our portfolio, we finished the year with a strong foundation for continued execution. As healthcare leaders navigate unprecedented complexit

    2/3/26 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Partners with Mosaic Life Care to Advance Patient Experience Across the Midwest

    Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organizations will work to elevate patient and employee experience across Mosaic's system, reinforcing its vision for Mosaic to be the region's first choice and most trusted partner in healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202915784/en/Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organ

    12/2/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Harrison Shane R covered exercise/tax liability with 21,271 shares, decreasing direct ownership by 12% to 150,729 units (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    1/26/26 6:10:11 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP, Strategic Insights Burik David was granted 100,000 shares (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    1/16/26 4:13:11 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Burik David

    3 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    1/16/26 4:09:08 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    SEC Filings

    View All

    National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    2/3/26 9:06:43 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by National Research Corporation

    10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

    11/7/25 1:03:21 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    10/27/25 5:03:13 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Research Corporation

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    11/13/24 4:05:19 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by National Research Corporation (Amendment)

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/8/24 4:05:05 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/5/24 4:31:31 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    View All

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Shane Harrison as Chief Financial Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare experience, is pleased to announce the appointment of Shane Harrison as its incoming Executive Vice President and Chief Financial Officer, effective on or about September 25, 2025. Chief Financial Officer Shane Harrison is a seasoned finance leader with more than 25 years of experience spanning corporate finance, investor relations, and strategic transactions. He most recently served as Senior Vice President – Finance and Investor Relations at PowerSchool, a leading K-12 education SaaS provider, since 2022. Prior to that, he served as Senior Vice President – Corporate Develop

    8/28/25 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation Appoints Trent Green as Chief Executive Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

    3/4/25 4:01:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Financials

    Live finance-specific insights

    View All

    NRC Health Announces Fourth Quarter 2025 Results

    Fourth quarter TRCV* increased 8% year-over-year to $144.1 million Cash flow from operations increased 13% year-over-year to $7.2 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the fourth quarter 2025. "Our fourth quarter results reflect the strong, disciplined execution happening across NRC Health and the deep trust our customers place in us," said Trent Green, CEO of NRC Health. "With TRCV reaching $144 million and momentum building across our portfolio, we finished the year with a strong foundation for continued execution. As healthcare leaders navigate unprecedented complexit

    2/3/26 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Third Quarter 2025 Results

     Third quarter TRCV* increased 8% year-over-year to $141.7 million Cash flow from operations increased 46% year-over-year to $13.8 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the third quarter 2025. "We delivered our fourth consecutive quarter of recurring contract value growth, driven by strong sales and meaningful improvement in customer retention," said Trent Green, CEO of NRC Health. "This sustained momentum reflects how our solutions deliver insights, engagement, and enablement that help healthcare organizations better understand, anticipate, and respond to the experience

    10/27/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Second Quarter 2025 Results

    Reports third consecutive quarter of sequential TRCV Growth National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2025. CEO Statement Trent S. Green, Chief Executive Officer of NRC Health, commented: "We're encouraged by our second-quarter results, which demonstrate continued momentum across key areas of our business. In my early weeks as CEO, I've been energized by feedback from both current and prospective customers, particularly their enthusiasm for our product portfolio and appreciation for the service mindset of our associates. To provide additional context on the quarter, we're reinstating our quarterly earnings call, which I

    7/28/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care